Cannabis occupies an awkward middle ground in drug classification: it is not a classic psychedelic like psilocybin or LSD, yet it can produce experiences that overlap strikingly with psychedelic states, including visual distortions, feelings of profound insight, and altered perception of time. The disconnect between its pharmacology and its subjective effects has puzzled researchers for decades. Whether you consider cannabis “psychedelic” depends heavily on the dose, the route of administration, the person taking it, and how strictly you define the term.
A Drug That Has Never Fit Neatly Into One Category
Cannabis has a classification problem that goes back to the earliest days of Western pharmacology. It was historically grouped with hallucinogens, partly because early case reports documented powerful psychoactive effects including anxiety, spiritual or mystical experiences, and changes to perception, awareness, and insight.1PubMed Central. “Hallucinations” Following Acute Cannabis Dosing: A Case Report and Comparison to Other Hallucinogenic Drugs Over time, as researchers learned more about how different substances interact with the brain, cannabis was moved out of the hallucinogen category and into its own class. Classic psychedelics like LSD and psilocybin work primarily by binding to serotonin 5-HT2A receptors. THC, the main psychoactive compound in cannabis, works through the endocannabinoid system by activating CB1 receptors, a fundamentally different mechanism.
That pharmacological distinction is real and important. But it has created a strange situation where the drug’s classification says one thing and the experience of taking it sometimes says another. More recent research has started to circle back, with some scientists including CB1 agonists alongside tryptamines, NMDA antagonists, and other compounds under a broader umbrella of “psychedelic” substances when studying neuroplasticity and neurogenesis.2PubMed Central. Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review The boundaries of the category remain actively contested.
What THC Actually Does to Your Brain
When THC enters your brain, it activates CB1 receptors that are densely concentrated in areas governing memory, mood, perception, and executive function. One of the more interesting findings involves the default mode network, a web of brain regions that is active when your mind wanders and that plays a central role in your sense of self. Classic psychedelics are famous for disrupting this network, which is thought to underlie the ego-dissolving experiences people report on psilocybin or LSD. THC also affects this network, though in a different way. In a controlled study of twenty healthy volunteers, THC significantly increased activity in task-irrelevant default-mode regions during a cognitive task, while leaving task-relevant regions unaffected.3PubMed Central. Default Mode Network in the Effects of Δ9-Tetrahydrocannabinol (THC) on Human Executive Function In plain terms, THC made the brain’s “daydreaming” circuits fire more loudly even when the person was supposed to be focused.
That finding resonates with the common experience of cannabis users: a drifting, associative quality of thought, the sense that your mind is wandering freely through ideas, and difficulty staying on task. It is a different signature from what LSD produces, but it is not trivial, and it does involve some of the same brain architecture. A study comparing neural activity under THC, LSD, and methamphetamine found that THC reduced alpha brainwave power, particularly in frontal regions, and that this reduction was associated with altered states of consciousness. LSD, by contrast, increased a measure called neural complexity. The two substances clearly affect the brain through different mechanisms, but both shift consciousness away from its ordinary resting state.4PubMed Central. Neural complexity is increased after low doses of LSD, but not moderate to high doses of oral THC or methamphetamine
When Cannabis Starts to Feel Genuinely Psychedelic
At low to moderate doses, most people experience cannabis as relaxing, mildly euphoric, and mildly perception-altering. Colors might seem richer, music more immersive, food more flavorful. These effects are real but are usually not what anyone would call psychedelic. The picture changes at higher doses. A controlled study gave healthy, infrequent cannabis users oral THC at two dose levels and found that THC dose-dependently increased measures of altered states of consciousness, including insightfulness, mindfulness, and mind-wandering.5PubMed Central. The altered state of consciousness induced by Δ9-THC The higher dose pushed participants into territory that starts to resemble what people report on classic psychedelics: a sense of expanded awareness and novel perspectives on familiar thoughts.
At genuinely high doses, the effects can go much further. In one documented case, a participant who received a high acute dose of THC in a research setting reported visual distortions where the floor appeared to sink away and patterns moved on the carpet and furniture. He also described a hypersensitivity to surrounding conversations without being able to understand specific words, and an out-of-body experience where he felt removed from his body and existing above it in space, accompanied by a sensation of paralysis.1PubMed Central. “Hallucinations” Following Acute Cannabis Dosing: A Case Report and Comparison to Other Hallucinogenic Drugs These are not garden-variety cannabis effects. They are, by any reasonable description, hallucinatory and dissociative experiences that closely parallel what happens with classic psychedelics.
Perhaps the most striking evidence comes from a pilot study that directly compared high-dose THC to high-dose psilocybin. Researchers administered 25 mg of THC (in synthetic form, dronabinol) alongside 25 mg of psilocybin and placebo in a classic psychedelic therapy setting. The high-dose THC produced a subjective experience similar to that of 25 mg psilocybin, and dronabinol was mistaken for a classic hallucinogen by both a psychedelic-naïve and a psychedelic-experienced participant.6Springer Link. Pilot study comparing the effects of high dose THC to high dose psilocybin and placebo in the set and setting of a classic psychedelic therapy session When the dose is high enough and the setting is right, even experienced psychonauts cannot tell the difference.
Why Edibles Produce Stronger Psychedelic-Like Effects
Anyone who has accidentally eaten too strong a cannabis edible knows the experience can be profoundly disorienting in ways that smoking rarely is. There is a biochemical reason for this. When you inhale cannabis, THC passes through the lungs into the bloodstream and reaches the brain quickly in its original form. When you eat it, THC is processed by the liver first, where enzymes convert a substantial portion of it into a metabolite called 11-hydroxy-THC. This metabolite is more psychoactive than THC itself, and blood analysis shows that levels of 11-hydroxy-THC are higher after ingestion than after smoking.7ScienceDirect. Cannabis edibles: dosing, encapsulation, and stability considerations
This metabolic conversion helps explain why edible experiences are more likely to veer into psychedelic territory, with vivid closed-eye imagery, time distortion, and occasionally full dissociative episodes. The delayed onset (typically 30 minutes to two hours) also means people frequently take more than intended before the first dose kicks in, compounding the issue. The practical takeaway is that the route of administration meaningfully changes the pharmacological profile of cannabis, making edibles a more potent vehicle for psychedelic-like effects than smoking or vaping the same total amount of THC.
How Terpenes and Other Compounds Shape the Experience
THC does not work in isolation inside the cannabis plant. It is accompanied by dozens of other cannabinoids and aromatic compounds called terpenes, which give different strains their distinctive smells. Research has shown that certain terpenes do not just add flavor; they directly interact with THC at the receptor level. When tested individually, several common cannabis terpenes activated CB1 receptors at roughly 10 to 50 percent of the level THC achieves alone. When combined with THC at ratios naturally found in the plant, some of these terpenes significantly amplified CB1 activation, in some cases by several fold, suggesting a genuine synergistic effect rather than simple addition.8PubMed. Selected cannabis terpenes synergize with THC to produce increased CB1 receptor activation
This matters for the psychedelic question because it means two cannabis products with identical THC percentages can produce meaningfully different subjective experiences depending on their terpene profiles. Some researchers have also identified non-cannabinoid plant components that may act as antidotes to THC’s intoxicating effects, potentially increasing its therapeutic index.9PubMed Central. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects The popular concept of the “entourage effect” is based on this idea. From a practical standpoint, it means that the strain, the growing conditions, and the extraction method all influence whether a particular cannabis product tilts toward mild relaxation or something more perceptually intense.
Psychedelic-Like or Psychotic-Like? An Important Distinction
The psychedelic-like effects of cannabis come with a caveat that classic psychedelics largely do not: cannabis experiences can shade into something that looks more like psychosis than like a therapeutic psychedelic journey. When researchers surveyed people who had lived experience with both psychosis and various drug-induced altered states, and asked which drug most closely resembled their psychotic symptoms, the majority endorsed cannabis. Classic psychedelics ranked lower, behind dissociative anesthetics and stimulants. The researchers concluded that interpreting psychedelic-induced experiences as broadly psychosis-like may be misleading, and that cannabis occupies a different, more psychotomimetic space.10SpringerLink. Do Psychedelics Mimic Psychosis? Perspectives on Similarities and Differences from Individuals with Lived Experience of Psychosis and Psychedelics
This is an underappreciated point. Classic psychedelics like psilocybin and LSD tend to produce experiences characterized by a sense of connectedness, emotional openness, and insight, even when the trip is difficult. Cannabis at high doses can produce those things too, but it is more likely to also produce paranoia, disorganized thinking, and perceptual disturbances that feel threatening rather than illuminating. The overlap with psychedelic phenomenology is real, but the overlap with psychotic phenomenology is also real, and which direction a given experience tilts depends heavily on the individual.
Why the Same Dose Hits People So Differently
One of the most striking things about cannabis compared to classic psychedelics is the enormous variability in how people respond. Some individuals can consume large quantities with minimal perceptual changes, while others experience vivid hallucinations from modest doses. Genetics plays a significant role. A large study of over 100,000 participants from the UK Biobank found that genetic risk for schizophrenia, measured through polygenic risk scores, significantly interacted with cannabis use to predict rates of psychotic experiences. Among the fifth of participants with the highest genetic risk, cannabis use was associated with about 1.6 times greater odds of psychotic experiences overall, compared to about 1.4 times greater odds among the fifth with the lowest risk. The pattern was especially pronounced for delusions of reference, which had no significant association with cannabis use except among those in the top two-fifths of genetic risk.11Translational Psychiatry. Cannabis, schizophrenia genetic risk, and psychotic experiences: a cross-sectional study of 109,308 participants from the UK Biobank
Beyond polygenic risk, specific genetic variants appear to influence susceptibility to cannabis-induced hallucinations. A genome-wide association study identified a significant signal near the gene for a cholinergic receptor, rather than dopaminergic targets, as a predisposing factor for cannabis-induced hallucinations.12PubMed. Cannabis induced psychosis: A systematic review on the role of genetic polymorphisms The involvement of cholinergic pathways is unexpected and suggests the pharmacology of cannabis-induced hallucinations may differ from both classic psychedelic hallucinations and schizophrenia-related hallucinations in ways we do not yet fully understand. The bottom line for any individual person is that your particular neurobiology affects whether cannabis stays mellow or goes somewhere more intense, and there is currently no practical way to test for this in advance.
Synthetic Cannabinoids Are a Different and More Dangerous Story
Products marketed as “synthetic marijuana” or “Spice” deserve a separate mention because they illustrate what happens when you take the CB1 receptor mechanism to its extreme. Natural THC is a partial agonist of CB1 receptors, meaning it activates them but does not push them to their maximum response. Synthetic cannabinoids are full agonists, meaning they drive CB1 activation much harder. This difference translates directly into more severe effects: synthetic cannabinoids are associated with higher rates of toxicity and hospital admissions than natural cannabis, and their commonly reported effects include hallucinations, delusions, agitation, confusion, and tachycardia.13PubMed. Synthetic Cannabinoids
The hallucinogenic effects of synthetic cannabinoids are considerably more intense and unpredictable than those of natural cannabis. If natural cannabis occasionally produces psychedelic-like experiences at high doses, synthetic cannabinoids can produce full-blown hallucinatory crises even at doses users consider normal. These products exploit the same receptor system but with none of the moderating influence of the plant’s other compounds, and none of the partial-agonist ceiling that keeps natural THC from driving the system into overdrive.
What Happens When Cannabis Meets Classic Psychedelics
Many people who use psychedelics also use cannabis, sometimes simultaneously. A large prospective survey found that using cannabis alongside classic serotonergic psychedelics intensified the psychedelic experience in a dose-dependent way. Higher doses of cannabis were linearly associated with stronger scores on measures of mystical experience, visual alterations, and ego dissolution.14Springer Link. Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey The two substances appear to potentiate each other, even though they act on different receptor systems.
This finding is consistent with the broader picture emerging from the research: cannabis is not a classic psychedelic, but its effects on consciousness overlap enough with psychedelic states that the two can interact synergistically. It also suggests that the boundary between psychedelic and non-psychedelic substances is fuzzier than the receptor-based classification system implies. A drug does not need to bind to 5-HT2A receptors to amplify mystical experience or ego dissolution; disrupting the brain’s ordinary patterns of information processing through any sufficiently powerful mechanism may be enough.
The Role of Set, Setting, and Expectation
The pilot study that found 25 mg of THC could be mistaken for psilocybin was conducted in a structured psychedelic therapy setting, complete with eyeshades, curated music, and trained guides. That context matters enormously. The same dose of THC consumed while scrolling your phone on the couch would likely produce a very different experience. Set and setting, the mental state you bring and the environment you are in, shape psychedelic experiences powerfully, and the same principle applies to cannabis. When your intention, environment, and dose are all aligned toward introspection, cannabis is more likely to produce the kind of deep, perception-shifting experience that people associate with psychedelics. When any of those factors are misaligned, the same dose is more likely to produce anxiety, confusion, or paranoia.
This helps explain why casual recreational users and therapeutic researchers sometimes seem to be describing entirely different drugs. The pharmacology creates a potential for psychedelic-like effects; whether that potential is realized depends on everything surrounding the molecule. Classic psychedelics are potent enough to produce their signature effects even in unfavorable conditions, which is part of why they are classified the way they are. Cannabis requires more cooperation from the context, which is part of why it is not.
Where CBD Fits Into the Picture
Most of the research discussed above focuses on THC in isolation or in high-THC cannabis products. But many cannabis products contain significant amounts of cannabidiol (CBD), which modulates THC’s effects in complex ways. CBD does not produce psychedelic-like effects on its own. In fact, it appears to dampen some of THC’s more disorienting properties, including anxiety and psychotomimetic effects. This means that the ratio of THC to CBD in a given cannabis product substantially influences whether the experience leans toward the perceptually mild or the perceptually strange. High-THC, low-CBD strains and concentrates are much more likely to produce psychedelic-like effects than balanced or CBD-dominant products. The trend in legal cannabis markets toward ever-higher THC concentrations, often exceeding 25 or 30 percent in flower and far higher in concentrates, has effectively increased the likelihood that users will encounter psychedelic-like effects whether they are looking for them or not.